Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
LEXX is expected to report earnings to rise 21.43% to -17 cents per share on January 21
Q4'25
Est.
$-0.17
Q3'25
Beat
by $0.02
Q2'25
Missed
by $0.05
Q1'25
Est.
$-0.17
Q4'24
Missed
by $0.08
The last earnings report on October 29 showed earnings per share of -14 cents, beating the estimate of -15 cents. With 1.46M shares outstanding, the current market capitalization sits at 13.94M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. LEXX showed earnings on October 29, 2025. You can read more about the earnings report here.